{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:51:19Z","timestamp":1794336679108,"version":"4.9.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,28]]},"abstract":"<jats:p>In a retrospective analysis, Dickerson et al report that the incidence of hypertension in patients treated with ibruitinib is nearly 80% and is associated with an increased rate of adverse cardiovascular events, primarily atrial fibrillation. Cardiac events can be reduced by treating the hypertension.<\/jats:p>","DOI":"10.1182\/blood.2019000840","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T15:05:11Z","timestamp":1570115111000},"page":"1919-1928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":251,"title":["Hypertension and incident cardiovascular events following ibrutinib initiation"],"prefix":"10.1182","volume":"134","author":[{"given":"Tyler","family":"Dickerson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, James Cancer Hospital and Solove Research Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Wiczer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, James Cancer Hospital and Solove Research Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, James Cancer Hospital and Solove Research Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Philippon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, James Cancer Hospital and Solove Research Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Porter","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-7720","authenticated-orcid":false,"given":"Devin","family":"Haddad","sequence":"additional","affiliation":[{"name":"Cardio-oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1174","authenticated-orcid":false,"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[{"name":"Cardio-oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bhat","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-8333","authenticated-orcid":false,"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[{"name":"Cardio-oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019112811583793800_B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"2019112811583793800_B2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2019112811583793800_B3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019112811583793800_B4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2019112811583793800_B5","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019112811583793800_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju204","article-title":"Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells","volume":"106","author":"Gao","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2019112811583793800_B7","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019112811583793800_B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","article-title":"Bruton\u2019s tyrosine kinase (BTK) as a promising target in solid tumors","volume":"58","author":"Molina-Cerrillo","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2019112811583793800_B9","unstructured":"222 Studies found for: ibrutinib. U.S. National Library of Medicine\n          . Available at https:\/\/clinicaltrials.gov\/ct2\/results?term=ibrutinib&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=. Accessed 19 February 2019."},{"issue":"1","key":"2019112811583793800_B10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2019112811583793800_B11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"issue":"21","key":"2019112811583793800_B12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2019112811583793800_B13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2019112811583793800_B14","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2019112811583793800_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.5657.5657","article-title":"An observational study of the occurrence of atrial fibrillation and hypertension in patients treated with ibrutinib [abstract]","volume":"124","author":"Binsah","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019112811583793800_B16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","volume":"18","author":"O\u2019Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2019112811583793800_B17","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"17","key":"2019112811583793800_B18","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"22","key":"2019112811583793800_B19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2019112811583793800_B20","unstructured":"Division of Cancer Treatment and Diagnosis\n          . Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bethesda, MD: National Cancer Institute; 2017. Available at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 30 June 2018."},{"issue":"2","key":"2019112811583793800_B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2019112811583793800_B22","first-page":"e67","article-title":"Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association [published correction appears in Circulation. 2018;137(12):e493]","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"2019112811583793800_B23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-148-2-200801150-00005","article-title":"A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study","volume":"148","author":"Parikh","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019112811583793800_B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"9604","key":"2019112811583793800_B25","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"32","key":"2019112811583793800_B26","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019112811583793800_B27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019112811583793800_B28","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2019112811583793800_B29","doi-asserted-by":"crossref","first-page":"e0122735","DOI":"10.1371\/journal.pone.0122735","article-title":"Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study","volume":"10","author":"Srikanthan","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2019112811583793800_B30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(09)70362-6","article-title":"Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer","volume":"11","author":"Stone","year":"2010","journal-title":"Lancet Oncol"},{"issue":"29","key":"2019112811583793800_B31","doi-asserted-by":"crossref","first-page":"20855","DOI":"10.18632\/oncotarget.25024","article-title":"Hypertension in malignancy-an underappreciated problem","volume":"9","author":"Ma\u0142yszko","year":"2018","journal-title":"Oncotarget"},{"issue":"suppl 15","key":"2019112811583793800_B32","article-title":"Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience [abstract]","volume":"35","author":"Gashonia","year":"2017","journal-title":"J Clin Oncol."},{"issue":"25","key":"2019112811583793800_B33","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019112811583793800_B34","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2019112811583793800_B35","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"11","key":"2019112811583793800_B36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2019112811583793800_B37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019112811583793800_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1701.1701","article-title":"Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma [abstract]","volume":"124","author":"Dreyling","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019112811583793800_B39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood-2015-01-621466","article-title":"Response: additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019112811583793800_B40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous Inhibition of PI3K\u03b4 and PI3K\u03b1 Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2019112811583793800_B41","doi-asserted-by":"crossref","first-page":"e1057385","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2015","journal-title":"OncoImmunology"},{"issue":"24","key":"2019112811583793800_B42","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2019112811583793800_B43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019112811583793800_B44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1253\/circj.72.293","article-title":"Association between blood pressure variability and inflammatory marker in hypertensive patients","volume":"72","author":"Kim","year":"2008","journal-title":"Circ J"},{"issue":"2","key":"2019112811583793800_B45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"2019112811583793800_B46","doi-asserted-by":"crossref","first-page":"26543","DOI":"10.1038\/srep26543","article-title":"Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"2019112811583793800_B47","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1919\/1543070\/bloodbld2019000840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1919\/1543070\/bloodbld2019000840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T11:59:04Z","timestamp":1574942344000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/22\/1919\/375010\/Hypertension-and-incident-cardiovascular-events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":47,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000840","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736709023.793582411","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]}}}